Physician profile
Christopher Henry
NPI 1881837995
$55,905.80
in general payments reported to CMS, 2019-2025
24 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,469 · 2020: $1,567 · 2021: $2,768 · 2022: $11K · 2023: $7,820 · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $4,229 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,269 · Travel and Lodging: $2,026 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,935.50 |
| Food and Beverage | $4,229.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,268.75 |
| Travel and Lodging | $2,025.65 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16,765.68 | 2023-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $15,664.03 | 2022-2025 | Xipere, Visudyne |
| Eyepoint US, INC. | $10,949.29 | 2021-2024 | |
| Alimera Sciences, INC. | $6,579.82 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,393.29 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $828.97 | 2020-2025 | Eylea Hd, Eylea |
| Penumbra, INC. | $572.78 | 2025 | Indigo System |
| Abbvie INC. | $520.72 | 2020-2025 | |
| Astellas Pharma US INC | $286.83 | 2023-2025 | Izervay |
| Allergan, INC. | $277.68 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $183.92 | 2022-2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $175.36 | 2023-2025 | Syfovre |
| Shockwave Medical, INC | $160.38 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Pharmaceuticals, INC. | $127.11 | 2022 | |
| Biogen, INC. | $72.93 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Coherus Oncology, INC. | $59.12 | 2023 | |
| Inari Medical, INC. | $54.85 | 2019 | |
| Amgen INC. | $41.21 | 2025 | Tavneos, Tepezza |
| Ani Pharmaceuticals, INC. | $39.56 | 2025 | Iluvien |
| Genentech, INC. | $31.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.48 | 2019 | |
| Medtronic, INC. | $13.96 | 2025 | Abre |
| Cashflow Solutions, LLC | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.